Novel Phenyl Derivatives
Novel phenyl derivatives uncouple oxidative phosphorylation to address the toxicity issues of DNP, providing a safer means to regulate mitochondrial activity and treat obesity and diabetes by increasing energy expenditure.
Patent Information
- Authority / Receiving Office
- JP Β· JP
- Patent Type
- Applications
- Current Assignee / Owner
- RIVUS PHARMACEUTICALS INC
- Filing Date
- 2026-01-30
- Publication Date
- 2026-05-26
AI Technical Summary
Current mitochondrial uncoupling agents, such as 2,4-dinitrophenol (DNP), are toxic and pose significant safety risks, necessitating the development of a safer alternative to regulate mitochondrial activity for obesity and metabolic disorders like diabetes and diabetic complications.
Development of novel phenyl derivatives, specifically 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole compounds or their pharmaceutically acceptable salts, which uncouple oxidative phosphorylation to increase energy expenditure without the toxicity of DNP.
The novel compounds effectively reduce obesity, treat metabolic disorders, and manage weight gain by safely increasing energy expenditure, demonstrating lower toxicity and improved safety profiles compared to DNP.
Smart Images
Figure 2026086513000046 
Figure 2026086513000047 
Figure 2026086513000048